Stoke Therapeutics, Inc. (NASDAQ:STOK) Expected to Post FY2028 Earnings of $0.17 Per Share

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at HC Wainwright cut their FY2028 earnings estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $0.17 per share for the year, down from their previous forecast of $0.18. HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.28) per share.

A number of other research analysts have also commented on STOK. Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. TD Cowen raised shares of Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. upped their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a research report on Tuesday, March 26th. Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Wedbush boosted their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $20.57.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded up $0.41 during trading hours on Thursday, hitting $12.01. 312,990 shares of the company traded hands, compared to its average volume of 949,112. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40. The business's 50-day moving average is $10.30 and its 200-day moving average is $6.72. The stock has a market capitalization of $625.96 million, a price-to-earnings ratio of -5.07 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to the consensus estimate of $3.70 million.

Insider Activity at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 11,150 shares of the business's stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares of the company's stock, valued at $423,035. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Skorpios Trust sold 3,600,000 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total value of $41,760,000.00. Following the sale, the insider now directly owns 10,843,681 shares in the company, valued at approximately $125,786,699.60. The disclosure for this sale can be found here. Insiders sold a total of 3,622,741 shares of company stock valued at $41,935,115 in the last three months. Company insiders own 11.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System purchased a new position in shares of Stoke Therapeutics in the first quarter worth about $141,000. Chase Investment Counsel Corp purchased a new position in shares of Stoke Therapeutics during the 1st quarter valued at approximately $279,000. BNP Paribas Financial Markets increased its stake in shares of Stoke Therapeutics by 86.2% during the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company's stock worth $193,000 after purchasing an additional 6,636 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Stoke Therapeutics in the 1st quarter worth about $1,224,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of Stoke Therapeutics during the first quarter worth approximately $405,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.